User profiles for SAVERIO CINIERI

saverio cinieri

Oncologia medica
Verified email at ieo.it
Cited by 11854

First-line FOLFOX plus panitumumab versus 5FU plus panitumumab in RAS-BRAF wild-type metastatic colorectal cancer elderly patients: The PANDA study.

…, F Buggin, L Antonuzzo, B Merelli, G Boscolo, S Cinieri… - 2020 - ascopubs.org
4002 Background: Data on first-line treatment efficacy in elderly patients are limited. Many
analyses adopt a questionable cut-off of 65 years and specific evidence with anti-EGFRs is low…

Efficacy of Metronomic Oral Vinorelbine, Cyclophosphamide, and Capecitabine vs Weekly Intravenous Paclitaxel in Patients With Estrogen Receptor–Positive, ERBB2 …

E Munzone, MM Regan, S Cinieri, E Montagna… - JAMA …, 2023 - jamanetwork.com
Importance In spite of the effectiveness of endocrine therapy plus cyclin-dependent kinase (CDK)
4/6 inhibitors as the first-line treatment for estrogen receptor (ER)-positive, erb-b2 …

[HTML][HTML] Management of patients with end-stage renal disease undergoing chemotherapy: recommendations of the Associazione Italiana di Oncologia Medica (AIOM) …

…, T Rampino, S Delfanti, S Brugnatelli, S Cinieri - Esmo Open, 2017 - Elsevier
Background The overall risk of some cancers is increased in patients receiving regular
dialysis treatment due to chronic oxidative stress, a weakened immune system and enhanced …

The MITO8 phase III international multicenter randomized study testing the effect on survival of prolonging platinum-free interval (PFI) in patients with ovarian cancer …

…, C Sacco, I Vergote, G Cormio, E Breda, S Cinieri… - 2016 - ascopubs.org
5505 Background: A longer PFI is associated with better outcomes in patients with OC. It has
long been hypothesized that artificially prolonging PFI by introducing a non-platinum based …

Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review

M Airoldi, D Amadori, S Barni, S Cinieri… - Tumori …, 2011 - journals.sagepub.com
Background Anthracycline-containing regimens have demonstrated significant disease-free
and overall survival benefits in the adjuvant setting and also provide palliative benefit in …

Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo …

…, H Castro, V Chan, V Charu, S Cinieri… - The Lancet …, 2020 - thelancet.com
Background CLEOPATRA was a phase 3 study comparing the efficacy and safety of pertuzumab,
trastuzumab, and docetaxel with placebo, trastuzumab, and docetaxel in patients with …

Left ventricular dysfunction predicted by early troponin I release after high-dose chemotherapy

…, M Civelli, G Lamantia, S Cinieri… - Journal of the American …, 2000 - jacc.org
OBJECTIVES We investigated the role of cardiac troponin I (cTnI) in patients with aggressive
malignancies treated with high-dose chemotherapy (HDC). BACKGROUND High dose …

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer …

…, M Karoly, R Gabor, C John, K Catherine, C Saverio… - The Lancet, 2020 - thelancet.com
Background Pembrolizumab monotherapy showed durable antitumour activity and manageable
safety in patients with metastatic triple-negative breast cancer. We aimed to examine …

Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial

…, E Breda, V Murgia, C Sacco, S Cinieri… - The lancet …, 2014 - thelancet.com
Background Carboplatin plus paclitaxel administered every 3 weeks is standard first-line
chemotherapy for patients with advanced ovarian cancer. A weekly paclitaxel schedule …

Breast carcinoma in elderly women: features of disease presentation, choice of local and systemic treatments compared with younger postmenopausal patients

…, M Intra, P Veronesi, G Renne, S Cinieri… - … Journal of the …, 2004 - Wiley Online Library
BACKGROUND Aging remains one of the single greatest risk factors for the development of
new breast carcinoma. The aim of the study was to evaluate the relation between biologic …